SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-246904
Filing Date
2021-08-16
Accepted
2021-08-16 07:16:04
Documents
15
Period of Report
2021-08-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d62829d8k.htm   iXBRL 8-K 27463
2 EX-99.1 d62829dex991.htm EX-99.1 99036
3 EX-99.2 d62829dex992.htm EX-99.2 10668
7 GRAPHIC g62829snap111.jpg GRAPHIC 6335
  Complete submission text file 0001193125-21-246904.txt   291885

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA tsha-20210816.xsd EX-101.SCH 2882
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20210816_lab.xml EX-101.LAB 18887
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20210816_pre.xml EX-101.PRE 11853
8 EXTRACTED XBRL INSTANCE DOCUMENT d62829d8k_htm.xml XML 3474
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 211174482
SIC: 2836 Biological Products, (No Diagnostic Substances)